Resources

In Part 1 of this Exclusive Interview, Dr. Lois Jovanovic joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida for a discussion about normalizing blood glucose during pregnancy in order to deliver a baby of healthy weight and avoid hyperinsulinima as well as curb the cycle of unhealthy children.

In part 2 of this Exclusive Interview, DIC Publisher Steve Freed asks about the success of anti-VEGF agents with lower A1Cs.

In this week's Homerun Slides, prioritizing patient characteristics to determine best type 2 treatment agent.

Transport of proinsulin from the ER to Golgi apparatus: After proinsulin is translocated into the lumen of the ER, it is then delivered in transport “COP-coated vesicles” to the cis-Golgi apparatus. Up until relatively recently, it was thought that newly synthesized proinsulin was passed from the cis-Golgi network “stack” via the medial- to the trans-stack of the Golgi apparatus stacks in “COP”-coated vesicles,

Part 2 of our ADA Rundown checks out the latest information on competing long-acting insulins, and the ongoing research into potential class effect benefits for cardiovascular outcomes: as data shows CV benefits for DPP-4 and SGLT-2 treatments, are GLP-1 treatments under pressure?

In part 1 of our ADA Rundown, we look at cardiovascular benefits for multiple drugs, new combination treatments, and the possibility that Invokana's weight loss benefits may also apply to people who don't have diabetes.

Would you be interested in seeing the news briefings from the ADA meeting? Topics include beta-cell replacement, closed loop systems, CVD and diabetes, etc., and feature all the top doctors on each. They last about 45 minutes. Follow the link to cast your vote!

Male, 32 years of age. Works erratic hours. Recently came up with a plan of how to remember to take his meds. He started setting up and taking his pill box with him. He has succeeded at taking his medications and taking them on time…all except his injectable medications.

In part 1 of this Exclusive Interview, Dr. Paul Chous discusses the significance of studies around the three anti-VEGF injections that seek to determine which is the best.

In this week's Homerun Slides, the Canadian Diabetes Association's guidelines for the pharmacologic treatment of type 2 diabetes, which dictate that the choice of therapy depends on glycemia.